Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.63 |
| ▸ | TP53 | P04637 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961949 | 1.00 | KIF11 (0.63) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL9961948 | 0.94 | KIF11 (0.72) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL8402610 | 0.94 | KIF11 (0.72) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL4928041 | 0.92 | KIF11 (0.57) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL4924334 | 0.92 | LMNA (0.56) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL765163 | 0.92 | TP53 (0.55) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL764793 | 0.86 | TP53 (0.58) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL11912922 | 0.86 | TP53 (0.64) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL14678935 | 0.84 | TP53 (0.58) | KIF11TP53LMNAMAPTABCG2 | |
| SCHEMBL11912895 | 0.83 | KIF11 (0.59) | KIF11TP53MAPTABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | HDGF, VEGFA, FLT4 | KIF11 1658/4885TP53 61/4885LMNA 3379/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KIF11 2569/4885TP53 16/4885LMNA 1803/4885 |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KIF11 2569/4885TP53 16/4885LMNA 1803/4885 |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | VHL, NGF, VEGFA | KIF11 1626/4885TP53 99/4885LMNA 1622/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | KIF11 2855/4885TP53 156/4885LMNA 1455/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | KIF11 1065/4885TP53 17/4885LMNA 1893/4885 |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | VEGFA, FLT4, FLT1 | KIF11 1215/4885TP53 34/4885LMNA 3985/4885 |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | ACP3, BPHL, PTGFR | KIF11 1310/4885TP53 380/4885LMNA 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.